Tom Ryu

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Divergent risk profiles for cause-specific mortality in MASLD and MetALD: a nationwide population-based study.

Divergent risk profiles for cause-specific mortality in MASLD and MetALD: a nationwide population-based study.

Journal: Frontiers in medicine

Published: March 17, 2026

Liver fibrosis burden and risk of incident arrhythmia in metabolic dysfunction-associated steatotic liver disease.

Liver fibrosis burden and risk of incident arrhythmia in metabolic dysfunction-associated steatotic liver disease.

Journal: Scientific reports

Published: March 06, 2026

High Cardiometabolic Risk Burden Predicts Adverse Outcomes in Patients with MASLD-Related Hepatocellular Carcinoma.

High Cardiometabolic Risk Burden Predicts Adverse Outcomes in Patients with MASLD-Related Hepatocellular Carcinoma.

Journal: Gut and liver

Published: November 30, 2025

Class-Specific Effects of ARBs Versus ACE Inhibitors on Survival and Cardiovascular Outcomes in MASLD.

Class-Specific Effects of ARBs Versus ACE Inhibitors on Survival and Cardiovascular Outcomes in MASLD.

Journal: International journal of molecular sciences

Published: August 26, 2025

Alcohol-Induced Oxidative Stress and Gut-Liver-Brain Crosstalk: Expanding the Paradigm from ALD to MetALD.

Alcohol-Induced Oxidative Stress and Gut-Liver-Brain Crosstalk: Expanding the Paradigm from ALD to MetALD.

Journal: Antioxidants (Basel, Switzerland)

Published: August 19, 2025

Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma.

Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma.

Journal: Biomedicines

Published: May 01, 2025

The prognostic impact of statin exposure in metabolic dysfunction-associated steatotic liver disease: a cohort study.

The prognostic impact of statin exposure in metabolic dysfunction-associated steatotic liver disease: a cohort study.

Journal: Translational gastroenterology and hepatology

Published: April 28, 2025

Prolonged Intestinal Ethanol Absorption and Oxidative Stress: Revisiting the Gut-Liver Axis in Alcohol-Associated Disease.

Prolonged Intestinal Ethanol Absorption and Oxidative Stress: Revisiting the Gut-Liver Axis in Alcohol-Associated Disease.

Journal: International journal of molecular sciences

Published: April 22, 2025

Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease.

Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: March 10, 2025

Correspondence to editorial on "Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C".

Correspondence to editorial on "Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C".

Journal: Clinical and molecular hepatology

Published: February 15, 2025

Multivitamin supplementation and its impact in metabolic dysfunction-associated steatotic liver disease.

Multivitamin supplementation and its impact in metabolic dysfunction-associated steatotic liver disease.

Journal: Scientific reports

Published: January 04, 2025

A comprehensive analysis of the impact of smoking on adverse clinical outcomes of steatotic liver diseases.

A comprehensive analysis of the impact of smoking on adverse clinical outcomes of steatotic liver diseases.

Journal: Therapeutic advances in gastroenterology

Published: December 03, 2024

Showing 1-12 of 32

Last Updated: 09/26/2026